- $4.68bn
- $4.57bn
- $493.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 414.15 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.77 | ||
| Price to Tang. Book | 60.32 | ||
| Price to Free Cashflow | 2,960.78 | ||
| Price to Sales | 8.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -11.39% | ||
| Return on Equity | -17.72% | ||
| Operating Margin | -10.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 51.13 | 139.67 | 276.98 | 383.47 | 493.63 | 603.09 | 711.62 | 135.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -40.59 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
Directors
- Donald Milder NEC (65)
- William Hoffman PRE (52)
- Mitchell Hill CFO (61)
- Andrew Hykes COO (47)
- Thomas Tu OTH (47)
- Rebecca Chambers IND (43)
- Cynthia Lucchese IND (60)
- Dana Mead IND (62)
- Kirk Nielsen IND (46)
- Jonathan Root IND (61)
- Catherine Szyman IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- July 25th, 2011
- Public Since
- May 22nd, 2020
- No. of Shareholders
- 10
- No. of Employees
- 1,300
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 58,563,592
- Address
- 6001 Oak Canyon, Suite 100, IRVINE, 92618
- Web
- https://www.inarimedical.com
- Phone
- +1 9499234747
- Auditors
- BDO USA, LLP
Upcoming Events for NARI
Inari Medical Inc Annual Shareholders Meeting
Q1 2025 Inari Medical Inc Earnings Release
Q2 2025 Inari Medical Inc Earnings Release
Similar to NARI
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Inari Medical share price?
As of Today at 20:16 UTC, shares in Inari Medical are trading at $79.93. This share price information is delayed by 15 minutes.
How has the Inari Medical share price performed this year?
Shares in Inari Medical last closed at $79.93 and the price had moved by +35.41% over the past 365 days. In terms of relative price strength the Inari Medical share price has outperformed the S&P500 Index by +10.85% over the past year.
What are the analyst and broker recommendations for Inari Medical?
The overall consensus recommendation for Inari Medical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Inari Medical dividend yield?
Inari Medical does not currently pay a dividend.
Does Inari Medical pay a dividend?
Inari Medical does not currently pay a dividend.
When does Inari Medical next pay dividends?
Inari Medical does not currently pay a dividend.
How do I buy Inari Medical shares?
To buy shares in Inari Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inari Medical?
As of the previous close price of $79.93, shares in Inari Medical had a market capitalisation of $4.68bn.
Where are Inari Medical shares listed?
Here are the trading details for Inari Medical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NARI
What kind of share is Inari Medical?
Based on an overall assessment of its quality, value and momentum Inari Medical is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inari Medical share price forecast for 2025?
The analyst consensus target price for shares in Inari Medical is $75.48. That is 5.57% below the last closing price of $79.93.
Analysts covering Inari Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.76 for the next financial year.
Find out moreWhat is the trend in the Inari Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inari Medical. Over the past six months, its share price has outperformed the S&P500 Index by +49.13%.
As of the last closing price of $79.93, shares in Inari Medical were trading +52.64% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inari Medical PE Ratio?
The Inari Medical PE ratio based on its reported earnings over the past 12 months is 414.15. The shares last closed at $79.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inari Medical?
Inari Medical's management team is headed by:
- Donald Milder - NEC
- William Hoffman - PRE
- Mitchell Hill - CFO
- Andrew Hykes - COO
- Thomas Tu - OTH
- Rebecca Chambers - IND
- Cynthia Lucchese - IND
- Dana Mead - IND
- Kirk Nielsen - IND
- Jonathan Root - IND
- Catherine Szyman - IND